 |
市场调查报告书
商品编码
1349862
黏多醣症(MPS)治疗市场:各治疗法，各MPS类型，各终端用户，各地区- 规模，占有率，展望，机会分析，2023年～2030年Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, By MPS Type, By End User, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
预计到 2023 年，全球黏多醣贮积症 (MPS) 治疗市场将达到 22.7 亿美元，预测期内（2023-2030 年）复合年增长率为 10.1%。
| 报告目标范围 | 报告详细内容 | ||
|---|---|---|---|
| 基准年 | 2022 | 2023年的市场规模 | 美国:22亿7,000万美元 |
| 过去资料 | 从2018年~ 2021年 | 预测期间 | 2023-2030 |
| 预测期间2023年～2030年 年复合成长率: | 10.10% | 2030年的价值预测 | 美国:44亿5,000万美元 |
Muco多醣症 (MPS) 的治疗主要着重于控制症状、改善生活品质和减缓疾病进展。MPS 是一组罕见的遗传性疾病，其特征是细胞和组织中糖胺聚醣 (GAG) 积聚，这是由于分解这些复杂糖的特定?缺乏所致。酵素替代疗法 (ERT)：这是许多类型 MPS 的主要治疗方法。在 ERT 中，透过静脉注射有缺陷或缺乏的酵素来帮助分解 GAG 积聚。虽然 ERT 有益，但它可能无法有效治疗神经系统疾病，因为酵素可能无法有效穿过血脑屏障。造血干细胞移植（HSCT）：造血干细胞移植也称为骨髓移植，涉及将捐赠者的健康干细胞移植到患者的骨髓中。供体细胞可以产生有缺陷的?，这可能会减少 GAG 的累积。在病程早期、重大不可逆损伤之前进行造血干细胞移植是最有效的。
市场动态
市场参与者正在关注各种无机成长策略，例如黏多醣贮积症（MPS）治疗的合作研究，预计这将推动全球黏多醣贮积症（MPS）治疗市场的成长。例如，2021年9月，武田製药宣布，它是一家全球生物製药公司，从患者的角度推动研发，旨在实现 "更好的健康" 和 "更光明的未来" 。与JCR Pharmaceuticals, Inc.合作，将其商业化下一代重组製剂JR-141，一种抗人转铁蛋白受体抗体和艾杜醣醛酸-2-硫酸酯?(IDS) 的融合蛋白，用于治疗亨特氏症候群。已达成合作伙伴关係和许可协议。根据该协议，武田在美国境外销售JR-141，包括加拿大、欧洲和其他地区（不包括日本和某些亚太国家）。JCR 将收到与此类非美国许可相关的预付款，并将有资格获得额外的开发和销售里程碑以及基于潜在销售的分级特许权使用费。
本调查的主要特征
- 本报告提供以2022年为基准年的预测期间（2023-2030 年）之全球黏多醣症(MPS)治疗市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
- 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
- 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
- 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球黏多醣症(MPS)治疗市场的主要参与者之企业简介。
- 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
- 全球黏多醣症(MPS)治疗市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
- 利益相关者可以透过全球黏多醣症(MPS)治疗市场用于分析的各种战略矩阵来帮助他们更容易做下决策。
目录
第1章 调查目的与前提条件
- 调查目的
- 前提条件
- 简称
第2章 市场概况
- 报告概要
- 市场定义和范围
- 摘要整理
- Coherent Opportunity Map(COM)
第3章 市场动态，法规，趋势分析
- 市场动态
- 促进因素
- 阻碍因素
- 市场机会
- 影响分析
- 最近的医药品上市
- 流行病学
- 合併，收购，联盟
- 法规情势
- 主要的发展
- PEST分析
第4章 黏多醣症(MPS)治疗的全球市场:COVID-19影响分析
- 经济影响
- COVID-19流行病学
- 供需的影响
第5章 黏多醣症(MPS)治疗的全球市场:不同治疗，2018-2030年
- 酵素补充疗法
- 干细胞疗法
第6章 黏多醣症(MPS)治疗的全球市场:各MPS类型，2018-2030年
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- 其他(MPS-III及MPS-IX)
第7章 黏多醣症(MPS)治疗的全球市场:各终端用户，2018年～2030年
- 医院
- 专门诊所
- 其他
第8章 黏多醣症(MPS)治疗的全球市场:各地区，2018-2030年
- 北美
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美国家
- 中东
- GCC
- 以色列
- 其他中东
- 非洲
- 北非
- 中非
- 南非
第9章 竞争情形
- 企业简介
- Takeda Pharmaceutical Company Limited
- 设备·组合
- BioMarin Pharmaceuticals, Inc.
- 设备·组合
- Ultragenyx Pharmaceutical Inc.
- 设备·组合
- Sarepta Therapeutics
- 设备·组合
- Abeona Therapeutics Inc.
- 设备·组合
- Eloxx Pharmaceuticals
- 设备组合
- Esteve
- 设备组合
- Immusoft Corporation
- 设备组合
- Inventiva
- 设备组合
- GC Pharma
- 设备组合
- JCR Pharmaceuticals Co Ltd.
- 设备组合
- RegenxBio Inc.
- 设备组合
- Sangamo Therapeutics, Inc.
- 设备组合
- Bioasis Technologies Inc.
- 设备组合
- Paradigm Biopharmaceuticals Ltd.
- 设备组合
第10章 章节
- 参考文献
- 调查手法
The global mucopolysaccharidosis (MPS) treatment market is estimated to be valued at US$ 2.27 Bn in 2023 and is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.27 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 10.10% | 2030 Value Projection: | US$ 4.45 Bn |
The treatment of Mucopolysaccharidosis (MPS) is primarily focused on managing symptoms, improving the quality of life, and slowing down the progression of the disease. MPS is a group of rare genetic disorders characterized by the accumulation of glycosaminoglycans (GAGs) in cells and tissues due to deficiencies in specific enzymes responsible for breaking down these complex sugars. Enzyme Replacement Therapy (ERT): This is the mainstay treatment for many types of MPS. In ERT, the missing or deficient enzyme is administered intravenously to help break down the accumulated GAGs. Although ERT can be beneficial, it may not effectively treat neurological symptoms because the enzyme may not efficiently cross the blood-brain barrier. Hematopoietic Stem Cell Transplantation (HSCT): Also known as bone marrow transplantation, HSCT involves transplanting healthy stem cells from a donor into the patient's bone marrow. The donor cells can produce the missing enzyme, leading to a potential reduction in GAG accumulation. HSCT is most effective when performed early in the disease course before significant irreversible damage has occurred.
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations for the treatment mucopolysaccharidosis (MPS), which is expected to boost the global mucopolysaccharidosis (MPS) treatment market growth. For instance, In September 2021, Takeda Pharmaceuticals, a patient-focused, R&D-driven, global biopharmaceutical company committed to bringing Better Health and a Brighter Future, entered into an exclusive collaboration and license agreement with JCR Pharmaceuticals is a global specialty pharmaceuticals company, to commercialize JR-141, an investigational next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome. Under the terms of the agreement, Takeda commercialized JR-141 outside of the U.S., including Canada, Europe, and other regions (excluding Japan and certain other Asia Pacific countries). JCR received an upfront payment for such an ex-US license and is eligible to receive additional development and commercial milestones, as well as tiered royalties on potential sales.
Key features of the study:
- This report provides an in-depth analysis of the global mucopolysaccharidosis (MPS) treatment market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
- Global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market.
Detailed Segmentation:
- Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment:
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type:
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- Others (MPS-III and MPS-IX)
- Global Mucopolysaccharidosis (MPS) Treatment Market, By End User:
- Hospitals
- Specialty Clinics
- Others
- Global Mucopolysaccharidosis (MPS) Treatment, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited
- BioMarin Pharmaceuticals, Inc.
- Ultragenyx Pharmaceutical Inc.
- Sarepta Therapeutics
- Abeona Therapeutics Inc.
- Eloxx Pharmaceuticals
- Esteve
- Immusoft Corporation
- Inventiva
- GC Pharma
- JCR Pharmaceuticals Co Ltd.
- RegenxBio Inc.
- Sangamo Therapeutics, Inc.
- Bioasis Technologies Inc.
- Paradigm Biopharmaceuticals Ltd.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By MPS Type
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Mucopolysaccharidosis (MPS) Treatment Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
- Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
6. Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- MPS-I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-VI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-VII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Others (MPS-III and MPS-IX)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
7. Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
8. Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country/Region, and Y-o-Y Growth 2018-2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BioMarin Pharmaceuticals, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sarepta Therapeutics
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abeona Therapeutics Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eloxx Pharmaceuticals
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Esteve
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Immusoft Corporation
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Inventiva
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GC Pharma
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- JCR Pharmaceuticals Co Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RegenxBio Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bioasis Technologies Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paradigm Biopharmaceuticals Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
10. Section
- References
- Research Methodology
- About us and Sales Contact
